Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Globe Newswire (Thu, 13-Aug 7:10 AM ET)
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Globe Newswire (Mon, 3-Aug 8:00 AM ET)
Pelthos Therapeutics Shifts Annual Meeting Date by Over 30 Days—What It Means for Shareholders
Market Chameleon (Mon, 27-Jul 7:34 AM ET)
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Globe Newswire (Fri, 24-Jul 5:00 PM ET)
Globe Newswire (Tue, 30-Jun 4:15 PM ET)
Globe Newswire (Tue, 30-Jun 7:30 AM ET)
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Pelthos Therapeutics trades on the AMEX stock market under the symbol PTHS.
As of September 4, 2026, PTHS stock price declined to $24.35 with 17,739 million shares trading.
PTHS has a beta of 1.78, meaning it tends to be more sensitive to market movements. PTHS has a correlation of 0.08 to the broad based SPY ETF.
PTHS has a market cap of $93.22 million. This is considered a Micro Cap stock.
Last quarter Pelthos Therapeutics reported $16 million in Revenue and -$6.62 earnings per share. This beat revenue expectation by $216,888 and missed earnings estimates by -$3.66.
The top ETF exchange traded funds that PTHS belongs to (by Net Assets): VTI, VXF.
PTHS has underperformed the market in the last year with a price return of -25.1% while the SPY ETF gained +19.8%. PTHS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.8% and -4.5%, respectively, while the SPY returned +2.0% and +0.6%, respectively.
PTHS support price is $22.90 and resistance is $25.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTHS shares will trade within this expected range on the day.